The CBR4 Knockout A-549 Polyclonal Cells offer a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the A-549 lung adenocarcinoma cell line. This knockout model enables the functional interrogation of CBR4 in a human epithelial context, providing a versatile tool for investigating mitochondrial redox biology and xenobiotic metabolism. The polyclonal nature of the edited pool captures a range of genetic modifications without clonal selection, suitable for pooled population studies.
The parental A-549 cell line, originally isolated from a 58-year-old Caucasian male with lung carcinoma, exhibits a hypotriploid karyotype and retains characteristics of alveolar basal epithelium. As a well-characterized model for non-small cell lung cancer (NSCLC), A-549 cells are widely employed to study oncogenic signaling, drug response, and metabolic adaptation. Their epithelial origin and robust growth make them an ideal host for assessing the impact of CBR4 loss on cancer cell physiology.
CBR4, a mitochondrial NADPH-dependent quinone reductase, plays a critical role in cellular detoxification and reactive oxygen species (ROS) management by catalyzing the two-electron reduction of quinone substrates. Its expression is upregulated under oxidative stress through the action of transcription factors NRF2 and PPAR??, establishing a cytoprotective axis. Upon activation, CBR4 utilizes NADPH as an electron donor and functionally interacts with components of the mitochondrial respiratory chain to modulate electron flux. Downstream effects include the generation of reduced quinone species, attenuation of intracellular ROS levels, and suppression of apoptosis, thereby promoting cell survival. This mechanistic framework positions CBR4 at the nexus of redox control and energy metabolism.
In A-549 NSCLC cells, CBR4 is implicated in pathways that govern chemoresistance and tumor resilience. The knockout of CBR4 in this polyclonal population disrupts the NRF2/PPAR???CCBR4?CROS axis, allowing researchers to dissect how loss of this reductase sensitizes cancer cells to oxidative damage and chemotherapeutic agents. This model is particularly valuable for exploring the interplay between mitochondrial quinone metabolism, fatty acid elongation, and respiratory function, as well as for identifying synthetic lethal interactions or compensatory mechanisms that arise upon CBR4 disruption.
Typical applications of the CBR4 Knockout A-549 Polyclonal Cells include detailed analyses of drug metabolism, cancer redox biology, and mechanisms of chemoresistance using assays such as western blotting, RT-qPCR, intracellular ROS detection, cell viability and colony formation assays, drug sensitivity profiling, and measurement of NADP/NADPH ratios. These polyclonal knockout cells serve as a robust platform for both hypothesis-driven and screening-based studies in academic and pharmaceutical research settings. For additional technical information or to request a quotation, please contact Ascent Research.
